期刊
CLINICS IN LIVER DISEASE
卷 20, 期 4, 页码 667-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2016.06.003
关键词
Cirrhosis; Regression; Viral suppression; Hepatocellular carcinoma; HIV; Portal hypertension; Stellate cell
资金
- NIH [R01 DK098819]
Great strides have been made in hepatitis B virus (HBV)-related fibrosis and cirrhosis. Available evidence indicates that HBV viral suppression causes regression of advanced fibrosis and even cirrhosis, and therefore should be attempted in all patients with advanced fibrosis and cirrhosis. The preferred agents in patients with cirrhosis are entecavir and tenofovir, primarily because the risk of breakthrough is low. HBV viral suppression leads to improved clinical outcomes even in patients with cirrhosis and complications. The risk of hepatocellular carcinoma is reduced, but not eliminated. Thus, patients with HBV cirrhosis should continue to have routine screening for hepatocellular carcinoma, even after viral suppression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据